Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Key facts

Sponsor

Indiana University

Principal Investigator

James E Tisdale, PharmD

Purdue University

Intervention

Progesterone(drug)

Enrollment

27 enrolled

Eligibility

21 years · FEMALE

Timeline

2019 – 2024

Study locations (1)

• Indiana University, Indianapolis, Indiana, United States

Collaborators

American Heart Association · Purdue University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital long QT syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06887387
  Wearable Devices for Patient Monitoring in Long QT Syndrome
  Queen Mary University of London
• ENROLLING BY INVITATIONNANCT07233421
  Frequency of Hypoglycemia in Children With Beta-blocker Treated Long QT-syndrome
  Helsinki University Central Hospital
• RECRUITINGNANCT04336644
  Continuous Versus Intermittent cARdiac Electrical moNitorinG
  Washington University School of Medicine
• RECRUITINGNANCT05348564
  Comparing Direct vs Indirect Methods for Cascade Screening
  University of Maryland, Baltimore
• RECRUITINGNCT06087367
  Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
  Nantes University Hospital

See all trials for Congenital long QT syndrome →